LUKAS SCHEIBLER - 10 Feb 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: CHIEF INNOVATION OFFICER
Signature: /s/ David Watson, attorney-in-fact for Lukas Scheibler
Issuer symbol: APLS
Transactions as of: 10 Feb 2022
Net transactions value: -$393,447
Form type: 4
Filing time: 14 Feb 2022, 15:15:13 UTC
Previous filing: 10 Feb 2022
Next filing: 14 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Tax liability	$31,947	-678	-1.3%	$47.12	53,179	10 Feb 2022	Direct	F1
transaction	APLS	Common Stock	Options Exercise	$138,500	+10,000	+19%	$13.85	63,179	10 Feb 2022	Direct	F2
transaction	APLS	Common Stock	Sale	$500,000	-10,000	-16%	$50.00	53,179	10 Feb 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-10,000	-13%	$0.000000	65,000	10 Feb 2022	Common Stock	10,000	$13.85	Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents shares used to cover tax withholding on a Restricted Stock Unit release.
F2	This is a scheduled exercise from 10B5-1 trading plan.
F3	This is a scheduled sale from 10B5-1 trading plan.
F4	This represents a stock option grant made on 02/08/2019 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.